Sionna Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 |
|---|---|---|
| Operating income | -$89.0M | -$70.6M |
| Operating expenses | $89.0M | $70.6M |
| Cash from operations | -$66.3M | -$52.8M |
| Capital expenditure | $377,000 | $27,000 |
| Free cash flow | -$66.7M | -$52.8M |
| Total assets | $326.0M | $185.8M |
| Total liabilities | $19.1M | $19.1M |
Shares outstanding 45.2M · Free float 71.5%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.